Evidence map›Paper›PMID 38589645›Full record

SynthesisProstate cancer and prostatic diseases2024

Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials.

Mohamed Shelan, Vérane Achard, Felix Appiagyei, Lucas Mose, Thomas Zilli, Christian D Fankhauser, Constantinos Zamboglou, Osama Mohamad, Daniel M Aebersold, Richard Cathomas

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Prostate cancer and prostatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohamed Shelan *Department of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland. mohamed.shelan@insel.ch.ORCID 0000-0002-6477-6655
Vérane Achard *Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Felix AppiagyeiDepartment of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.
Lucas MoseDepartment of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.ORCID 0009-0006-0693-2716
Thomas ZilliFaculty of Medicine, University of Geneva, Geneva, Switzerland.
Christian D FankhauserDepartment of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland.
Constantinos ZamboglouDepartment of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Osama MohamadDepartment of Genito-urinary Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA.
Daniel M AebersoldDepartment of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.ORCID 0000-0002-9493-3834
Richard CathomasDepartment of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEnzalutamide, a second-generation androgen receptor inhibitor, is indicated for the treatment of metastatic disease, as well as in the treatment of non-metastatic castration resistant prostate cancer (PCa). This systematic review aims to determine outcomes and toxicity in patients with non-metastatic castration sensitive prostate cancer (nmCSPC) treated with enzalutamide in the primary or salvage settings.

methodWe performed a systematic review focusing on the role of Enzalutamide in the treatment of nmCSPC, using the PubMed/Medline database. Articles focusing on androgen receptor inhibitors in nmCSPC were included, while articles discussing exclusively metastatic or castration-resistant PCa were excluded.

resultsThe initial search retrieved 401 articles, of which 15 underwent a thorough assessment for relevance. Ultimately, 12 studies with pertinent outcomes were meticulously examined. Among these, seven studies were dedicated to the investigation of enzalutamide in the primary setting, while the remaining five publications specifically addressed its use in salvage settings. Regardless of the treatment setting, our data revealed two distinct therapeutic strategies. The first advocates for the substitution of enzalutamide for androgen deprivation therapy (ADT), based on the premise of achieving equivalent, if not superior, oncological outcomes while minimizing treatment-related toxicity. The second, adopting a more conventional approach, entails augmenting the effectiveness of ADT by incorporating enzalutamide.

conclusionEnzalutamide has considerable potential as a therapeutic strategy for nmCSPC, either used alone or in combination with ADT in the primary or in the salvage settings. The use of enzalutamide instead of ADT is an appealing strategy. However, more trials will be required to further understand the efficacy and side-effect profile of enzalutamide monotherapy.

Indexed as

BenzamidesNeoplasm Recurrence, LocalNitrilesPhenylthiohydantoinAndrogen Receptor AntagonistsClinical Trials as TopicHumansMaleProspective StudiesProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantSalvage TherapyAndrogen Receptor AntagonistsBenzamidesenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID38589645
PMCPMC11319196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.